

GREG WALDEN, OREGON  
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY  
RANKING MEMBER

ONE HUNDRED FIFTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

November 7, 2017

Mr. Charles Reuland  
Executive Vice President and Chief Operating Officer  
Johns Hopkins Hospital  
1800 Orleans Street  
Baltimore, MD 21287

Dear Mr. Reuland:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, October 11, 2017, to testify at the hearing entitled "Examining How Covered Entities Utilize the 340B Drug Pricing Program."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Tuesday, November 21, 2017. Your responses should be mailed to Ali Fulling, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to [Ali.Fulling@mail.house.gov](mailto:Ali.Fulling@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Greg Walden  
Chairman

cc: The Honorable Diana DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachment

Attachment—Additional Questions for the Record

The Honorable Buddy Carter

1. How many Part B beneficiaries utilized drugs covered under the 340B program last year at Johns Hopkins facilities?
2. What was the total dollar amount of 340B drugs dispensed to beneficiaries at Johns Hopkins under Part B under last year?
3. What was the total dollar amount of Part B drugs dispensed to beneficiaries each year from the year you entered the 340B program to last year?
4. Do you provide a reduction in out of pocket costs for Part B beneficiaries accessing drugs at Johns Hopkins or one of your ancillary sites?
5. Has there been an annual increase in the number of drugs purchased by Johns Hopkins for dispensing to Part B patients since you have entered the program? Please provide numbers detailing your program.
6. Can you provide your opinion as to why the Disproportionate Share Hospital (DSH) metric, which measures Medicare and Medicaid inpatient stays, is or is not appropriate for use in an outpatient drug program targeting underinsured and uninsured patients?
7. According to an October 2017 Health Affairs article, the national median for hospital DSH percentages is 12.0%, which raises questions about the appropriateness of the 11.75% threshold used for the 340B program. What is your DSH percentage?
  - a. Do you believe the DSH threshold for 340B hospitals should be adjusted to better target those 340B hospitals that have a DSH percentage well-above the national median?
8. What is the payer mix at your main 340B hospital site? How many uninsured or Medicaid patients are you serving? What is the percentage of commercially insured and Medicare patients?
9. Would you support a new 340B program requirement that mandates a certain level of charity care?
10. Are you aware of any instances in which your hospital did not pass on 340B savings to uninsured or underinsured patients?
11. Would you support new reporting/tracking requirements for 340B hospitals to achieve more consistency with respect to program savings?
12. An October 2017 Health Affairs article found that the national median for hospital operating margins is -0.8%. Can you please provide your hospital operating margin?
13. Is your payer mix the same at your child sites compared to your main hospital?